Biotechnology
Commented by André Will-Laudien on April 6th, 2022 | 10:46 CEST
Siemens Healthineers, Perimeter Medical, Siemens, SAP - After BioNTech, now the push for MedTech shares!
The most significant positive share price developments in the last 12 months occurred in the biotech sector, especially among vaccine manufacturers such as BioNTech and Moderna. The stock market overlooked that pandemics, and the fight against them, offer short-term profit opportunities. The great battle against widespread diseases such as cardiovascular disease, cancer or other previously incurable indications progresses steadily. Their diagnosis and treatment require many types of technology, devices, processes, analysis tools, and intelligent software. Some methods certainly deserve the attribute "disruptive technology". We take a look at some blockbusters in the MedTech segment.
Read
Commented by André Will-Laudien on April 4th, 2022 | 12:19 CEST
Bayer, Cardiol Therapeutics, Formycon, NanoRepro: Top Biotech Stocks - Delivering!
Due to various public easing measures, the Corona pandemic is increasingly fading into the background. It has long been a hot ride for the stock market, especially for vaccine producers, but now investors are shifting their focus to other stocks in the biotech segment. After all, there are still many diseases that confront humanity with unresolved mysteries, and the field of human medical research seems endless. We focus on interesting stocks from the sector, which corrected strongly in the wake of the Ukraine downturn but are now trending north again. These trends are still in their infancy.
Read
Commented by Nico Popp on April 4th, 2022 | 11:20 CEST
Millions with innovations: BioNTech, Meta Materials, Varta
When the long-forgotten solar company SolarWorld went public in 1999, n-tv ran commercials that, from today's perspective, looked rather amateurish. At that time, too, only a few private investors were initially convinced by the Company. Years later, SolarWorld was a success story - investors from the very beginning had become rich. Even though the Company filed for insolvency in the meantime and burned a lot of money - SolarWorld investors of the first hour are mostly still wealthy. We explain where innovations can develop blockbuster potential.
Read
Commented by André Will-Laudien on April 1st, 2022 | 12:43 CEST
BioNTech, Defence Therapeutics, Valneva, CureVac - Stocks with blockbuster potential!
With the Ukraine crisis, international vaccination activity has taken a back seat. The world's northern hemisphere is gearing up for next summer, so flu diseases are also slowly taking a back seat. However, the COVID virus will likely continue to mutate over the summer and will reappear in a new guise in the fall. Germany's maximum vaccination rate of 76% has been reached, with just under a quarter of the population ultimately foregoing vaccination after lengthy public measures. For the major biotech companies, it is now a case of - The country needs new products! There are still many areas of application in the field of mRNA. Which stocks stand out with their pipeline?
Read
Commented by Juliane Zielonka on March 29th, 2022 | 13:34 CEST
Valneva, Triumph Gold, BioNTech - Gold rush mood in the pipeline
While the Corona measures are eased in Spain, and the government lets symptom-free positive tested persons out of quarantine, Germany tightens again and extends the measures. This could create a gold-rush mood among BioNTech investors, as figures from the Mainz-based biotech Company will be announced on Wednesday. Valneva is also looking ahead with confidence to the first shipment of its liquid gold in the form of the COVID-19 inactivated vaccine. For investors with a more earthy disposition, it is a good idea to look at the real precious metals and gold deposits these days. For example, an investment in Canada's Triumph Gold Corporation offers copper and diamond deposits in addition to gold. The Company specializes in the discovery and development of gold and other valuable commodity deposits.
Read
Commented by Stefan Feulner on March 24th, 2022 | 13:07 CET
BioNTech, Cardiol Therapeutics, Moderna - New target groups to boost business
Infection figures remain at record levels. Health authorities reported 283,732 new infections to the Robert Koch Institute, 21,139 cases more than a week ago. In contrast, the pace of vaccination is limping, with the vaccination status of the overall population changing only marginally and remaining at 75.8% basic immunization. Chancellor Scholz is now calling for compulsory vaccination to counter the threat of another wave of Corona in the fall. This message is likely to be grist to the mill for the vaccine manufacturers, whose ratings, similar to the vaccination rates, have dropped sharply in recent weeks.
Read
Commented by Nico Popp on March 22nd, 2022 | 11:22 CET
In the right place at the right time: BioNTech, Defence Therapeutics, Bayer
For years, the pandemic has kept the world on tenterhooks. Currently, the epidemic is taking a break, at least in the media. But while the world is looking tautly at Ukraine and more and more refugees are arriving in Germany, the Omicron figures are rising once more. In some cases, the incidence in Germany is over 3,000. Although fewer and fewer people are dying, more people than ever are in quarantine. We look at BioNTech, a typical pandemic stock, and present other exciting investments from the healthcare sector.
Read
Commented by André Will-Laudien on March 21st, 2022 | 13:10 CET
Attention - MorphoSys, Valneva, CureVac, MAS Gold: These shares smell of a turnaround!
The biotech sector, especially around vaccine manufacturers, has recently fallen somewhat out of fashion - Germany's most extensive Corona measures have likely already taken place. The general willingness to vaccinate can hardly be increased, and the vaccination obligation was dropped without a trace after lawyers formed a massive wave of lawsuits. But now that the Omicron infection figures are exploding to unimagined heights, we can expect a hot autumn again after a summer with a breather. "Corona has come to stay!" said Karl Lauterbach when he was not yet health minister. We take a look at some shares that have recently rebounded strongly.
Read
Commented by Carsten Mainitz on March 14th, 2022 | 12:47 CET
BioNTech, Defence Therapeutics, MorphoSys - Shares with blockbuster potential!
Developing a blockbuster drug is the highest achievement in the pharmaceutical industry. A blockbuster is defined as a drug that can generate more than USD 1 billion in revenues per year. According to experts, the vaccine Comirnaty, developed by BioNTech and Pfizer, is likely to have brought in sales of well over USD 30 billion, thus clearly breaking the blockbuster barrier. Outside of vaccine research, there are also numerous companies with high long-term potential.
Read
Commented by Armin Schulz on March 7th, 2022 | 13:05 CET
Valneva, Defence Therapeutics, MorphoSys - Blockbuster potential
Every pharmaceutical or biotech company wants a blockbuster. This term refers to a drug that generates annual sales of at least USD 1 billion. The best-known blockbuster drug currently is the Corona vaccine from BioNTech. In 2020, the rheumatism drug Humira was in the top spot with sales of over USD 20 billion. The Mainz-based vaccine manufacturer is likely to have significantly surpassed this mark in 2021. If a company hits the big time, it can reap the rewards for 20 years before the patent expires. Today, we take a look at three companies that have potential blockbusters.
Read